A Novel Aldosterone Antagonist Limits Renal Injury... - BV FAPESP
Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy

Texto completo
Autor(es):
Mostrar menos -
Fujihara, Clarice K. ; Kowala, M. C. ; Breyer, M. D. ; Sena, Claudia R. ; Rodrigues, Mariliza V. ; Arias, Simone C. A. ; Fanelli, Camilla ; Malheiros, Denise M. ; Jadhav, P. K. ; Montrose-Rafizadeh, Chahrzad ; Krieger, Jose E. ; Zatz, Roberto
Número total de Autores: 12
Tipo de documento: Artigo Científico
Fonte: SCIENTIFIC REPORTS; v. 7, AUG 11 2017.
Citações Web of Science: 3
Resumo

Aldosterone antagonists slow the progression of chronic kidney disease (CKD), but their use is limited by hyperkalemia, especially when associated with RAS inhibitors. We examined the renoprotective effects of Ly, a novel non-steroidal mineralocorticoid receptor (MR) blocker, through two experimental protocols: In Protocol 1, male Munich-Wistar rats underwent 5/6 renal ablation (Nx), being divided into: Nx+V, receiving vehicle, Nx+Eple, given eplerenone, 150 mg/kg/day, and Nx+Ly, given Ly, 20 mg/kg/day. A group of untreated sham-operated rats was also studied. Ly markedly raised plasma renin activity (PRA) and aldosterone, and exerted more effective anti-albuminuric and renoprotective action than eplerenone. In Protocol 2, Nx rats remained untreated until Day 60, when they were divided into: Nx+V receiving vehicle; Nx+L treated with losartan, 50 mg/kg/day; Nx+L+Eple, given losartan and eplerenone, and Nx+L+Ly, given losartan and Ly. Treatments lasted for 90 days. As an add-on to losartan, Ly normalized blood pressure and albuminuria, and prevented CKD progression more effectively than eplerenone. This effect was associated with strong stimulation of PRA and aldosterone. Despite exhibiting higher affinity for the MR than either eplerenone or spironolactone, Ly caused no hyperkalemia. Ly may become a novel asset in the effort to detain the progression of CKD. (AU)

Processo FAPESP: 12/10926-5 - Patogênese e terapêutica da doença renal crônica: papel da imunidade inata na lesão de glomérulos, túbulos e interstício
Beneficiário:Roberto Zatz
Modalidade de apoio: Auxílio à Pesquisa - Temático